<DOC>
	<DOCNO>NCT02964325</DOCNO>
	<brief_summary>This prospective , multi-center , control , randomize , non-inferiority study evaluate clinical effectiveness Conventional versus Mirasol-treated apheresis platelet subject hypoproliferative thrombocytopenia expect platelet count ( ) ≤ 10,000/μL require ≥ 2 platelet transfusion .</brief_summary>
	<brief_title>Efficacy Mirasol-treated Apheresis Platelets Patients With Hypoproliferative Thrombocytopenia</brief_title>
	<detailed_description>Patients randomize 1:1 Mirasol-treated platelet ( test platelet ) conventional , untreated platelet ( control platelet ) . The blood center collect apheresis donor platelet supply test platelet hospital site transfusion patient . Hospital sit order control platelets per normal process , standard vendor . The target population MIPLATE study patient hematologic malignancy hypoproliferative thrombocytopenia expect platelet ( PLT ) count ( ) ≤ 10,000/μL require ≥ 2 PLT transfusion . The primary objective MIPLATE determine hemostatic efficacy Mirasol-treated plasma store Trima Accel® Aph PLTs non-inferior Conventional plasma store Aph PLTs subject hypoproliferative thrombocytopenia require PLT transfusion . The secondary objective include compare efficacy safety endpoint treatment group . Subjects hematologic malignancy hypoproliferative thrombocytopenia anticipate experience `` transfusion episode '' require PLT transfusion support bone marrow recovery . During period PLT transfusion require study subject give accord subject 's treatment allocation 28 day initial PLT transfusion OR transfusion independence ( 10 day without PLT transfusion ) prior Day 28 . Additionally , serum sample HLA antibody test collect weekly 28 day Days 42 56 . At minimum , initial post-randomization prophylactic PLT transfusion initiate PLT count ≤ 10,000/µL . Thereafter , indication PLT transfusion may PLT count-related prophylaxis , intervention-related prophylaxis , therapeutic ( treatment active bleeding ) determine treat physician ( ) . The indication ( ) transfusion ( ) capture .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>1 . Weight &gt; 10 kg ( 22 lb ) 2 . Subject hematologic malignancy hypoproliferative thrombocytopenia expect PLT count ( ) ≤ 10,000/µL require ≥ 2 PLT transfusion 3 . Laboratory result within 5 day prior anticipated initiation first post randomization PLT transfusion : 1 . Prothrombin time ( PT ) and/or international normalize ratio ( INR ) ≤ 1.3 × upper limit normal ( ULN ) 2 . Activated partial thromboplastin time ( aPTT ) ≤ 1.3 × ULN 3 . Fibrinogen ≥ 100 mg/dL 4 . Women childbearing potential must negative pregnancy test agree practice medically acceptable contraception regimen study duration . Women postmenopausal least 1 year ( &gt; 12 month since last menses ) surgically sterilize require test 5 . IC subject assent subject consent parent guardian , subject &lt; 18 year age 1 . Previous treatment pathogenreduced blood product 2 . Subject previously enrol study receive least 1 per protocol PLT transfusion 3 . Subject receive anticoagulant , procoagulant antithrombotic , antiplatelet agent , and/or PLT specific growth factor within 10 day prior randomization 4 . Subject ≥ grade 2 bleeding time randomization 5 . Planned administration bedside LR PLT transfusion ( ) 6 . Subject anticipate need wash volume reduce PLT course study 7 . Presently history acute promyelocytic leukemia ( APML ) , idiopathic thrombocytopenic purpura ( ITP ) , thrombotic thrombocytopenic purpura ( TTP ) , hemolytic uremic syndrome ( HUS ) 8 . Positive lymphocytotoxic antibody ( &gt; 20 % HLA panel reactive antibody ) screen and/or subject suspect refractory PLTs 9 . Splenomegaly ( presence palpable spleen whose border could felt 4 cm costal margin ) 10 . History diagnosis disease affect hemostasis 11 . Currently take , participate clinical study involve PLT substitute , PLT growth factor , pharmacologic agent intend enhance ( ie , antifibrinolytic agent ) decrease PLT hemostatic function 12 . Acute chronic medical disorder , opinion investigator , would impair ability subject receive protocol treatment 13 . Subject pregnant lactating 14 . Inability subject comply study procedure and/or followup</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>hypoproliferative thrombocytopenia</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>platelet therapy</keyword>
	<keyword>apheresis</keyword>
	<keyword>pathogen reduction therapy</keyword>
</DOC>